Trending Topic

15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1 Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2 It is conventionally performed via the trans-femoral (TF) route. Recently, however, the trans-radial (TR) route has become the preferred way.3 The TR route offers better procedure comfort, shorter hospitalization […]

Riyaz Bashir, TCT 2022: The Bashir endovascular catheter for pulmonary embolism

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 29th 2022

Mortality remains high in patients with high and intermediate risk pulmonary embolism (PE). The Bashir endovascular catheter device, designed for use in large vessels, aims to improve patient outcomes. In this touchCARDIO interview, we speak with Dr Riyaz Bashir (Temple University Hospital, Philadelphia, PA, USA) to discuss the unmet needs in PE and the Bashir endovascular catheter device.

The abstract entitled ‘A Prospective Multicenter Trial of Pharmaco-Mechanical Catheter-Directed Thrombolysis With the BASHIRâ„¢ Endovascular Catheter for Intermediate-Risk Acute Pulmonary Embolism – The RESCUE Study’ was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.

Questions:

  1. What are the unmet needs in the treatment of pulmonary embolism? (0:22)
  2. Could you give us a brief overview of the Bashir endovascular catheter? (1:36)

Disclosures: Riyaz Bashir is on the advisory board and speaker’s bureau for Thrombolex Inc. and a consultant for the company. He has received honorarium and grant/research support from Thrombolex Inc. and is a major stock shareholder.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of TCT 2022

Access more content on Devices here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup